Dose Finding Study of L19TNF and Doxorubicin in Patients With STS

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 5, 2019

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions

Soft Tissue Sarcoma

Interventions

DRUG

L19TNF

L19TNF 13 µg/kg i.v. will be administered on day 1, 3 and 5 of each 21-day cycle

DRUG

DOXORUBICIN

Doxorubicin 75 mg/m2 will be administered on day 1 of each 21-day cycle

Trial Locations (1)

Sarcoma Oncology Research Center (SORC) Cancer Center of Southern California, Santa Monica

All Listed Sponsors

lead

Philogen S.p.A.

INDUSTRY

NCT04032964 - Dose Finding Study of L19TNF and Doxorubicin in Patients With STS | Biotech Hunter | Biotech Hunter